Cytosorbents Corporation

As of June 30, 2026, Cytosorbents Corporation carries a market capitalization of 23.50M, placing it among publicly traded companies globally. Its enterprise value stands at 48.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cytosorbents Corporation's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Cytosorbents Corporation has 3.14M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.63, and the price-to-book ratio stands at -31.30.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 48.52M versus a market cap of 23.50M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cytosorbents Corporation maintains a current ratio of 0.66, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -3,918.24, indicating conservative leverage, while an interest coverage ratio of -3.66 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -42.38, reflecting losses generated across the asset base. The company generates approximately 277,731.34 in revenue per employee across its workforce of 134.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.86 indicates how many times Cytosorbents Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cytosorbents Corporation recorded an income tax benefit of -401,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -18.61M and -18.21M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Cytosorbents Corporation's stock has declined approximately 64.65% over the past 52 weeks. The 50-day moving average sits at 5.59, while the 200-day moving average is 9.76.

Over the twelve months ended June 30, 2026, Cytosorbents Corporation generated 37.22M in revenue and converted that into -18.21M in net income, yielding earnings per share of -5.80. EBITDA reached -11.39M, while operating income came in at -12.15M.

As of June 30, 2026, Cytosorbents Corporation holds 4.41M in cash and equivalents against 29.43M in total debt, resulting in a net debt position of 12.83M. Total book value stands at -751,000.00, with working capital of -8.29M providing operational flexibility.

Cytosorbents Corporation produced -9.15M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -436,000.00 in capital expenditures, free cash flow totaled -9.58M - equivalent to -3.05 per share.

Over the twelve months ended June 30, 2026, Cytosorbents Corporation posted a gross margin of 71.61, reflecting its pricing power and cost economics. The operating margin of -32.64 and net profit margin of -48.94 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -40.82: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.54, meaning Cytosorbents Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cytosorbents Corporation's most recent stock split took place on September 8, 2026 with a 20:1 split ratio.

As of June 30, 2026, Cytosorbents Corporation has an Altman Z-Score of -12.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.